Rebecca Lehto, PhD, RN, OCN, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Rebecca Lehto, PhD, RN, OCN, assistant professor, College of Nursing, Michigan State University, discusses patient use of complementary modalities during treatment for advanced lung cancer.
Frontline Durvalumab Does Not Elicit Significant OS Improvement in Advanced, PD-L1-High NSCLC
December 29th 2022In the PEARL trial, monotherapy with durvalumab did not deliver a statistically significant improvement in overall survival vs platinum-based chemotherapy as frontline treatment in patients with PD-L1-high stage IV non–small cell lung cancer.
Are Hearing Tests Necessary For Adult Cancer Survivors?
September 15th 2022In this episode of “The Vitals,” Christine Miaskowski, PhD, RN, discusses research showcasing that adult patients receiving either a platinum-based chemotherapy, taxane alone, or a combined regimen of platinum- and taxane-based treatment may be at risk of hearing loss.
Adagrasib Receives Accelerated Approval for KRAS G12C Mutated NSCLC
December 13th 2022Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
Trifluridine/Tipiracil Plus Bevacizumab Improves OS in Refractory Metastatic Colorectal Cancer
2 Clarke Drive
Cranbury, NJ 08512